ARTICLE | Company News

Amgen files CERA complaint

April 13, 2006 12:31 AM UTC

AMGN filed a complaint with the U.S. International Trade Commission (ITC) on Tuesday requesting a permanent exclusion order that would prohibit Roche (SWX:ROCZ) from importing pegylated recombinant human erythropoietin (EPO) into the U.S. ITC is expected to decide whether to start a formal investigation within 30 days of the filing of the complaint. AMGN believes ROCZ's Continuous Erythropoiesis Receptor Activator (CERA), which is a single methoxy-polyethylene glycol polymer bound to an EPO molecule, infringes AMGN's patents covering pegylated EPO. ...